Evaluation of the Detection of Toll-like Receptors (TLRs) in Cancer Development and Progression in Patients with Colorectal Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Jun 9

PMID 29883450

Citations 24

Authors

Ippokratis Messaritakis

Maria Stogiannitsi

Asimina Koulouridi

Maria Sfakianaki

Alexandra Voutsina

Afroditi Sotiriou

Elias Athanasakis

Evangelos Xynos

Dimitris Mavroudis

Maria Tzardi

John Souglakos

Affiliations

Soon will be listed here.

Abstract

Background: Toll-like receptors (TLRs) play essential role in innate and acquired immunity, are expressed in various cell types, and are associated with altered susceptibility to many diseases, and cancers. The aim of this study was to investigate TLR2 (-196 to-174del), TLR4 (Asp299Gly and Thr399Ile) and TLR9 (T1237C and T1486C) gene polymorphisms at risk of colorectal cancer (CRC) development and progression.

Methods: Peripheral blood was obtained from 397 patients with adjuvant (stage II/III, n = 202) and metastatic (n = 195) CRC. Moreover, blood samples from 50 healthy volunteers and 40 patients with adenomatous polyps were also included as control groups. DNA from patients and controls was analyzed using PCR and PCR-RFLP for genotyping functional polymorphism within TLR2, TLR4 and TLR9 genotypes.

Results: TLR2-196 to-174del/del genotype was detected in 76.6% of the patients and was significantly higher that the controls groups (p<0.001). TLR4 Asp299Gly, TLR4 Thr399Ile, TLR9 T1237C and T1486C homozygous genotypes were detected in 70.5%, 70.5%, 61.5% and 61.5% of the patients respectively, and were also significantly higher than that in the control groups (p<0.001). All polymorphisms detected were also significantly associated with the metastatic disease (p<0.001) leading to shorter overall survival (p<0.001); whereas, TLR4 Asp299Gly and Thr399Ile polymorphisms were significantly associated with KRAS mutations.

Conclusions: The detection of higher frequencies of the TLR2, TLR4 and/or TLR9 polymorphisms in CRC patients compared with the control groups highlight the role of these polymorphism in CRC development and cancer progression.

Citing Articles

Investigation of TLR2 (-196 to -174del) and TLR9 (T-1486C) Gene Polymorphisms Association with Inflammatory Bowel Diseases.

Emele R, Salim M, Polat F, Diler S Asian Pac J Cancer Prev. 2024; 25(6):2003-2010.

PMID: 38918662 PMC: 11382830. DOI: 10.31557/APJCP.2024.25.6.2003.

Toll-like receptors in health and disease.

Wang K, Huang H, Zhan Q, Ding H, Li Y MedComm (2020). 2024; 5(5):e549.

PMID: 38685971 PMC: 11057423. DOI: 10.1002/mco2.549.

Gut Microbiota, Inflammatory Bowel Disease, and Cancer: The Role of Guardians of Innate Immunity.

Giambra V, Pagliari D, Rio P, Totti B, Di Nunzio C, Bosi A Cells. 2023; 12(22).

PMID: 37998389 PMC: 10669933. DOI: 10.3390/cells12222654.

Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study.

Messaritakis I, Psaroudaki E, Vogiatzoglou K, Sfakianaki M, Topalis P, Iliopoulos I Cancers (Basel). 2023; 15(19).

PMID: 37835512 PMC: 10571744. DOI: 10.3390/cancers15194819.

Evaluation of the Impact of Some Single-Nucleotide Gene Polymorphisms on the Development of Adenomatous Polyps of the Colon in Patients with Irritable Bowel Syndrome.

Kyrian O, Dorofeyev A, Derkach I, Zhigal Y Turk J Gastroenterol. 2023; 34(8):822-830.

PMID: 37404119 PMC: 10544543. DOI: 10.5152/tjg.2023.21985.

References

Pradere J, Dapito D, Schwabe R . The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2013; 33(27):3485-95. PMC: 4059777. DOI: 10.1038/onc.2013.302. View

P Torok H, Glas J, Endres I, Tonenchi L, Teshome M, Wetzke M . Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol. 2009; 104(7):1723-33. DOI: 10.1038/ajg.2009.184. View

Chen R, Alvero A, Silasi D, Steffensen K, Mor G . Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Oncogene. 2008; 27(2):225-33. DOI: 10.1038/sj.onc.1210907. View

Kinugasa T, Akagi Y . Status of colitis-associated cancer in ulcerative colitis. World J Gastrointest Oncol. 2016; 8(4):351-7. PMC: 4824713. DOI: 10.4251/wjgo.v8.i4.351. View

Tannock G . Molecular analysis of the intestinal microflora in IBD. Mucosal Immunol. 2008; 1 Suppl 1:S15-8. DOI: 10.1038/mi.2008.54. View

Hishida A, Matsuo K, Goto Y, Naito M, Wakai K, Tajima K . No associations of Toll-like receptor 2 (TLR2) -196 to -174del polymorphism with the risk of Helicobacter pylori seropositivity, gastric atrophy, and gastric cancer in Japanese. Gastric Cancer. 2010; 13(4):251-7. DOI: 10.1007/s10120-010-0567-y. View

Pandey S, Agrawal D . Immunobiology of Toll-like receptors: emerging trends. Immunol Cell Biol. 2006; 84(4):333-41. DOI: 10.1111/j.1440-1711.2006.01444.x. View

Holldack J . Toll-like receptors as therapeutic targets for cancer. Drug Discov Today. 2013; 19(4):379-82. DOI: 10.1016/j.drudis.2013.08.020. View

Ng M, Lau C, Chan T, Wong W, Lau Y . Polymorphisms of the toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese. Rheumatology (Oxford). 2005; 44(11):1456-7. DOI: 10.1093/rheumatology/kei120. View

10.

Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J . The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis. 2005; 11(7):645-52. DOI: 10.1097/01.mib.0000168372.94907.d2. View

11.

Makni L, Messadi A, Zidi S, Gazouani E, Mezlini A, Yacoubi-Loueslati B . TLR2 (-196 to -174 Ins/Del) and TLR3 (1377C>T) as biomarkers for nasopharyngeal cancer in Tunisia. Turk J Med Sci. 2017; 47(4):1216-1222. DOI: 10.3906/sag-1608-17. View

12.

Gelman A, Zhang J, Choi Y, Turka L . Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004; 172(10):6065-73. PMC: 2833313. DOI: 10.4049/jimmunol.172.10.6065. View

13.

Sheng W, Yong Z, Yun Z, Hong H, Hai L . Toll-like receptor 4 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Arch Med Sci. 2015; 11(4):699-707. PMC: 4548027. DOI: 10.5114/aoms.2015.53288. View

14.

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T . Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res. 2011; 17(20):6531-41. DOI: 10.1158/1078-0432.CCR-10-3376. View

15.

Slattery M, Herrick J, Bondurant K, Wolff R . Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer. 2011; 130(12):2974-80. PMC: 3290725. DOI: 10.1002/ijc.26314. View

16.

Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M . Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci. 2007; 98(11):1790-4. PMC: 11158170. DOI: 10.1111/j.1349-7006.2007.00590.x. View

17.

Priyadarshini A, Chakraborti A, Mandal A, Singh S . Asp299Gly and Thr399Ile polymorphism of TLR-4 gene in patients with prostate cancer from North India. Indian J Urol. 2013; 29(1):37-41. PMC: 3649598. DOI: 10.4103/0970-1591.109982. View

18.

Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S . Toll-like receptor signal transduction. Exp Mol Med. 2007; 39(4):421-38. DOI: 10.1038/emm.2007.47. View

19.

Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai R . MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med. 2010; 207(8):1625-36. PMC: 2916129. DOI: 10.1084/jem.20100199. View

20.

Yu L, Chen S . Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008; 57(9):1271-8. PMC: 11031105. DOI: 10.1007/s00262-008-0459-8. View